Home
INZY
INZY News

Latest Inozyme Pharma Inc. (INZY) News on June 21, 2025

Biotech Stock Roundup: BMRN to Acquire INZY, NVAX Gains on Vaccine Approval & More

Zacks

a month ago

Biotech Stock Roundup: BMRN to Acquire INZY, NVAX Gains on Vaccine Approval & More

Biotech Alert: Searches spiking for these stocks today

TipRanks

a month ago

Biotech Alert: Searches spiking for these stocks today

BioMarin Offers to Buy Inozyme for $270M to Boost Enzyme Therapy Biz

Zacks

a month ago

BioMarin Offers to Buy Inozyme for $270M to Boost Enzyme Therapy Biz

MT Newswires

a month ago

Piper Sandler Downgrades Inozyme Pharma to Neutral From Overweight, Lowers Price Target to $4 From $23

MT Newswires

a month ago

TD Cowen Downgrades Inozyme Pharma to Hold From Buy, Price Target is $4

MT Newswires

a month ago

Raymond James Downgrades Inozyme Pharma to Market Perform From Outperform

MT Newswires

a month ago

Needham Downgrades Inozyme Pharma to Hold From Buy

BioMarin agrees to acquire Inozyme for $270m

Pharmaceutical Technology

a month ago

BioMarin agrees to acquire Inozyme for $270m

BioMarin Expands Rare Disease Portfolio with $270M Inozyme Acquisition

Insider Monkey

a month ago

BioMarin Expands Rare Disease Portfolio with $270M Inozyme Acquisition

BioMarin Bolsters Pipeline With $270 Million Inozyme Pharma Takeover

Investor's Business Daily

a month ago

BioMarin Bolsters Pipeline With $270 Million Inozyme Pharma Takeover

MT Newswires

a month ago

Sector Update: Health Care

MT Newswires

a month ago

BioMarin Pharmaceutical to Acquire Inozyme Pharma for $270 Million

BioMarin Strengthens Enzyme Therapy Business with Acquisition of Inozyme Pharma

PR Newswire

a month ago

BioMarin Strengthens Enzyme Therapy Business with Acquisition of Inozyme Pharma

Inozyme Pharma Reports First Quarter 2025 Financial Results and Provides Business Highlights

GlobeNewswire

a month ago

Inozyme Pharma Reports First Quarter 2025 Financial Results and Provides Business Highlights

Inozyme Pharma Announces JBMR Plus Publication Demonstrating Real-World Impact of ENPP1 Deficiency

GlobeNewswire

2 months ago

Inozyme Pharma Announces JBMR Plus Publication Demonstrating Real-World Impact of ENPP1 Deficiency

Inozyme Pharma to Participate in the 24th Annual Needham Virtual Healthcare Conference

GlobeNewswire

3 months ago

Inozyme Pharma to Participate in the 24th Annual Needham Virtual Healthcare Conference

MT Newswires

3 months ago

Wedbush Cuts Inozyme Pharma Price Target to $7 From $12, Maintains Outperform Rating

Inozyme Pharma Reports Full Year 2024 Financial Results and Announces Strategic Prioritization of ENPP1 Deficiency Pivotal Program and Recent Business Highlights

GlobeNewswire

3 months ago

Inozyme Pharma Reports Full Year 2024 Financial Results and Announces Strategic Prioritization of ENPP1 Deficiency Pivotal Program and Recent Business Highlights

Inozyme Pharma to Present at the TD Cowen 45th Annual Health Care Conference

GlobeNewswire

4 months ago

Inozyme Pharma to Present at the TD Cowen 45th Annual Health Care Conference

Inozyme Pharma to Present Recently Announced Interim Data for INZ-701 in Infants and Young Children with ENPP1 Deficiency at CHOP Cardiology 2025

GlobeNewswire

4 months ago

Inozyme Pharma to Present Recently Announced Interim Data for INZ-701 in Infants and Young Children with ENPP1 Deficiency at CHOP Cardiology 2025

Inozyme Pharma Announces Positive Interim Data for INZ-701 in Infants and Young Children with ENPP1 Deficiency and Key Program Updates

GlobeNewswire

5 months ago

Inozyme Pharma Announces Positive Interim Data for INZ-701 in Infants and Young Children with ENPP1 Deficiency and Key Program Updates

MT Newswires

6 months ago

Raymond James Initiates Inozyme Pharma at Outperform With $26 Price Target

Inozyme Pharma to Participate in the Piper Sandler 36th Annual Healthcare Conference

GlobeNewswire

7 months ago

Inozyme Pharma to Participate in the Piper Sandler 36th Annual Healthcare Conference

Here's Why Inozyme Pharma (INZY) is Poised for a Turnaround After Losing -29.98% in 4 Weeks

Zacks

7 months ago

Here's Why Inozyme Pharma (INZY) is Poised for a Turnaround After Losing -29.98% in 4 Weeks

Inozyme Pharma to Present at Upcoming Investor Conferences

GlobeNewswire

7 months ago

Inozyme Pharma to Present at Upcoming Investor Conferences

Inozyme Pharma Reports Third Quarter 2024 Financial Results and Provides Business Highlights

GlobeNewswire

8 months ago

Inozyme Pharma Reports Third Quarter 2024 Financial Results and Provides Business Highlights

MT Newswires

8 months ago

Inozyme Pharma Reports Positive Interim Data From Trial of Potential Kidney Disease Treatment

Inozyme Pharma Announces Positive Interim Data from Phase 1 SEAPORT 1 Trial of INZ-701

GlobeNewswire

8 months ago

Inozyme Pharma Announces Positive Interim Data from Phase 1 SEAPORT 1 Trial of INZ-701

Inozyme Pharma Announces Presentation of Interim Data from Phase 1 SEAPORT 1 Trial at the Upcoming American Society of Nephrology (ASN) Kidney Week 2024

GlobeNewswire

8 months ago

Inozyme Pharma Announces Presentation of Interim Data from Phase 1 SEAPORT 1 Trial at the Upcoming American Society of Nephrology (ASN) Kidney Week 2024

Inozyme Pharma Announces Appointment of Biopharmaceutical Commercial Leader Erik Harris to its Board of Directors

GlobeNewswire

8 months ago

Inozyme Pharma Announces Appointment of Biopharmaceutical Commercial Leader Erik Harris to its Board of Directors

Inozyme Pharma Presents New Data at the American Society for Bone and Mineral Research (ASBMR) 2024 Annual Meeting

GlobeNewswire

9 months ago

Inozyme Pharma Presents New Data at the American Society for Bone and Mineral Research (ASBMR) 2024 Annual Meeting

MT Newswires

9 months ago

Stifel Initiates Inozyme Pharma at Buy With $16 Price Target

Inozyme Pharma to Participate at the 2024 Wells Fargo Healthcare Conference

GlobeNewswire

10 months ago

Inozyme Pharma to Participate at the 2024 Wells Fargo Healthcare Conference

Jefferies Predicts up to 270% Rally for These 2 ‘Strong Buy’ Stocks

TipRanks

10 months ago

Jefferies Predicts up to 270% Rally for These 2 ‘Strong Buy’ Stocks

Institutional owners may consider drastic measures as Inozyme Pharma, Inc.'s (NASDAQ:INZY) recent US$49m drop adds to long-term losses

Simply Wall St.

10 months ago

Institutional owners may consider drastic measures as Inozyme Pharma, Inc.'s (NASDAQ:INZY) recent US$49m drop adds to long-term losses

Inozyme Pharma Reports Second Quarter 2024 Financial Results and Provides Business Highlights

GlobeNewswire

10 months ago

Inozyme Pharma Reports Second Quarter 2024 Financial Results and Provides Business Highlights

Inozyme Pharma Publishes Preclinical Data Supporting INZ-701 as a Potential Therapy for a Broad Range of Serious Rare Diseases Impacting Bone Health and Blood Vessel Function

GlobeNewswire

a year ago

Inozyme Pharma Publishes Preclinical Data Supporting INZ-701 as a Potential Therapy for a Broad Range of Serious Rare Diseases Impacting Bone Health and Blood Vessel Function

MT Newswires

a year ago

Inozyme Pharma Says US FDA Granted Fast Track Designation to INZ-701 to Treat ABCC6 Deficiency

Inozyme Pharma Announces FDA Fast Track Designation for INZ-701 in ABCC6 Deficiency

GlobeNewswire

a year ago

Inozyme Pharma Announces FDA Fast Track Designation for INZ-701 in ABCC6 Deficiency

Why Did Inozyme Pharma, Inc. (INZY) Get a Strong Buy Rating from Analysts?

Insider Monkey

a year ago

Why Did Inozyme Pharma, Inc. (INZY) Get a Strong Buy Rating from Analysts?

Inozyme Pharma Announces Presentation and Sponsored Symposium at the 11th International Conference on Children’s Bone Health (ICCBH)

GlobeNewswire

a year ago

Inozyme Pharma Announces Presentation and Sponsored Symposium at the 11th International Conference on Children’s Bone Health (ICCBH)

MT Newswires

a year ago

Wells Fargo Starts Inozyme Pharma With Overweight Rating, $14 Price Target

Inozyme Pharma to Present at the Jefferies Global Healthcare Conference

GlobeNewswire

a year ago

Inozyme Pharma to Present at the Jefferies Global Healthcare Conference

Inozyme Pharma to Present Recently Announced Data from Phase 1/2 Trials of INZ-701 in Adults with ENPP1 Deficiency and ABCC6 Deficiency (PXE) at Upcoming Medical Conferences

GlobeNewswire

a year ago

Inozyme Pharma to Present Recently Announced Data from Phase 1/2 Trials of INZ-701 in Adults with ENPP1 Deficiency and ABCC6 Deficiency (PXE) at Upcoming Medical Conferences

Inozyme Pharma to Participate at the Bank of America Securities 2024 Health Care Conference

GlobeNewswire

a year ago

Inozyme Pharma to Participate at the Bank of America Securities 2024 Health Care Conference

Inozyme Pharma Reports First Quarter 2024 Financial Results and Provides Business Highlights

GlobeNewswire

a year ago

Inozyme Pharma Reports First Quarter 2024 Financial Results and Provides Business Highlights

Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

a year ago

Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Inozyme Pharma Announces Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency (PXE) and ENPP1 Deficiency

GlobeNewswire

a year ago

Inozyme Pharma Announces Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency (PXE) and ENPP1 Deficiency

Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

a year ago

Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Inozyme Pharma to Participate at the 23rd Annual Needham Virtual Healthcare Conference

GlobeNewswire

a year ago

Inozyme Pharma to Participate at the 23rd Annual Needham Virtual Healthcare Conference

Inozyme Pharma to Report Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency and ENPP1 Deficiency on April 8, 2024

GlobeNewswire

a year ago

Inozyme Pharma to Report Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency and ENPP1 Deficiency on April 8, 2024

Inozyme Pharma Reports Full Year 2023 Financial Results and Provides Business Highlights

GlobeNewswire

a year ago

Inozyme Pharma Reports Full Year 2023 Financial Results and Provides Business Highlights

Inozyme Pharma to Participate in the TD Cowen 44th Annual Health Care Conference

GlobeNewswire

a year ago

Inozyme Pharma to Participate in the TD Cowen 44th Annual Health Care Conference

Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

a year ago

Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Overseas Shipholding Group Confirms Receipt of Unsolicited Indication of Interest

Business Wire

a year ago

Overseas Shipholding Group Confirms Receipt of Unsolicited Indication of Interest

Cass Information Systems Inc (CASS) Reports Mixed Q4 Results Amid Freight Recession

GuruFocus.com

a year ago

Cass Information Systems Inc (CASS) Reports Mixed Q4 Results Amid Freight Recession

Midland States Bancorp (MSBI) Q4 Earnings and Revenues Beat Estimates

Zacks

a year ago

Midland States Bancorp (MSBI) Q4 Earnings and Revenues Beat Estimates

Macatawa Bank Corporation Reports Fourth Quarter and Full Year 2023 Results

GlobeNewswire

a year ago

Macatawa Bank Corporation Reports Fourth Quarter and Full Year 2023 Results

Declining Stock and Decent Financials: Is The Market Wrong About Marine Products Corporation (NYSE:MPX)?

Simply Wall St.

a year ago

Declining Stock and Decent Financials: Is The Market Wrong About Marine Products Corporation (NYSE:MPX)?

Here’s Why Greenlight Capital Exited Southwestern Energy (SWN)

Insider Monkey

a year ago

Here’s Why Greenlight Capital Exited Southwestern Energy (SWN)

Associated Press Finance

a year ago

Bar Harbor: Q4 Earnings Snapshot

Bar Harbor Bankshares Reports Fourth Quarter 2023 Results

ACCESSWIRE

a year ago

Bar Harbor Bankshares Reports Fourth Quarter 2023 Results

IGI to Release Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024

Business Wire

a year ago

IGI to Release Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024

PREMIERE Group, One of the Nation’s Largest and Fastest Growing Mega Teams, Joins The Real Brokerage

Business Wire

a year ago

PREMIERE Group, One of the Nation’s Largest and Fastest Growing Mega Teams, Joins The Real Brokerage

Unpacking Q3 Earnings: BJ's (NASDAQ:BJRI) In The Context Of Other Sit-Down Dining Stocks

StockStory

a year ago

Unpacking Q3 Earnings: BJ's (NASDAQ:BJRI) In The Context Of Other Sit-Down Dining Stocks

Investors in Peapack-Gladstone Financial (NASDAQ:PGC) have unfortunately lost 22% over the last year

Simply Wall St.

a year ago

Investors in Peapack-Gladstone Financial (NASDAQ:PGC) have unfortunately lost 22% over the last year

Surmodics to Host Virtual Annual Meeting of Shareholders

Business Wire

a year ago

Surmodics to Host Virtual Annual Meeting of Shareholders

Amarin Provides Preliminary Fourth Quarter 2023 Selected Financials and Outlines Key Priorities For 2024

GlobeNewswire

a year ago

Amarin Provides Preliminary Fourth Quarter 2023 Selected Financials and Outlines Key Priorities For 2024

Investing in CapStar Financial Holdings (NASDAQ:CSTR) five years ago would have delivered you a 33% gain

Simply Wall St.

a year ago

Investing in CapStar Financial Holdings (NASDAQ:CSTR) five years ago would have delivered you a 33% gain

‘Go Head First Into 2024’: Talkspace Therapists Provide Simple, Actionable Steps For Prioritizing Mental Health This Year

Business Wire

a year ago

‘Go Head First Into 2024’: Talkspace Therapists Provide Simple, Actionable Steps For Prioritizing Mental Health This Year

Investing in Covenant Logistics Group (NASDAQ:CVLG) three years ago would have delivered you a 196% gain

Simply Wall St.

a year ago

Investing in Covenant Logistics Group (NASDAQ:CVLG) three years ago would have delivered you a 196% gain

Tortoise Provides Unaudited Balance Sheet Information and Asset Coverage Ratio Updates as of December 29, 2023, for TYG, NTG, TTP, NDP and TPZ

ACCESSWIRE

a year ago

Tortoise Provides Unaudited Balance Sheet Information and Asset Coverage Ratio Updates as of December 29, 2023, for TYG, NTG, TTP, NDP and TPZ

Avanos Medical, Inc. to Present at the 42nd Annual J.P. Morgan Healthcare Conference

PR Newswire

a year ago

Avanos Medical, Inc. to Present at the 42nd Annual J.P. Morgan Healthcare Conference

A Top Penn Entertainment Shareholder Seeks Board Seats

The Wall Street Journal

a year ago

A Top Penn Entertainment Shareholder Seeks Board Seats

From $10k to $100k in 5 years: 3 Small-Cap Stocks to Make a Fortune

InvestorPlace

a year ago

From $10k to $100k in 5 years: 3 Small-Cap Stocks to Make a Fortune

Institutional investors own a significant stake of 45% in Inozyme Pharma, Inc. (NASDAQ:INZY)

Simply Wall St.

a year ago

Institutional investors own a significant stake of 45% in Inozyme Pharma, Inc. (NASDAQ:INZY)

Cullinan Oncology to Present at the 42nd Annual J.P. Morgan Healthcare Conference

GlobeNewswire

2 years ago

Cullinan Oncology to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Modernize Unveils In-Depth Homeowner Insights Report: A Guide to Future-Proofing Your Business

Business Wire

2 years ago

Modernize Unveils In-Depth Homeowner Insights Report: A Guide to Future-Proofing Your Business

Savara Announces New Employment Inducement Grant

Business Wire

2 years ago

Savara Announces New Employment Inducement Grant

Seacoast Banking (SBCF) Moves 5.1% Higher: Will This Strength Last?

Zacks

2 years ago

Seacoast Banking (SBCF) Moves 5.1% Higher: Will This Strength Last?

Is SNDL Stock's Turnaround Finally Here?

Motley Fool

2 years ago

Is SNDL Stock's Turnaround Finally Here?

UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire

2 years ago

UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PR Newswire

2 years ago

Uranium Royalty Corp. Endorses Net-Zero Nuclear Industry Pledge at COP 28

Black Excellence is the Focus of PRA Group's Newest Employee Resource Group

CNW Group

2 years ago

Black Excellence is the Focus of PRA Group's Newest Employee Resource Group

Reflecting Accelerating Growth in Health Savings Accounts (HSAs), Mesirow Tapped by WEX to Serve as RIA

PR Newswire

2 years ago

Reflecting Accelerating Growth in Health Savings Accounts (HSAs), Mesirow Tapped by WEX to Serve as RIA

Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

2 years ago

Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sanara MedTech Inc.'s (NASDAQ:SMTI) top owners are retail investors with 32% stake, while 31% is held by insiders

Simply Wall St.

2 years ago

Sanara MedTech Inc.'s (NASDAQ:SMTI) top owners are retail investors with 32% stake, while 31% is held by insiders

Farmers National Banc (NASDAQ:FMNB) Will Pay A Dividend Of $0.17

Simply Wall St.

2 years ago

Farmers National Banc (NASDAQ:FMNB) Will Pay A Dividend Of $0.17

Top Technolgy Stocks for Q4 2023

Investopedia

2 years ago

Top Technolgy Stocks for Q4 2023

Pardon the Disruption: Can Amazon be a grocer and a 3P delivery provider?

Grocery Dive

2 years ago

Pardon the Disruption: Can Amazon be a grocer and a 3P delivery provider?

Uranium Royalty Corp. Releases Inaugural Sustainability Report

CNW Group

2 years ago

Uranium Royalty Corp. Releases Inaugural Sustainability Report

Kingsoft Cloud Holdings Limited (NASDAQ:KC) Q3 2023 Earnings Call Transcript

Insider Monkey

2 years ago

Kingsoft Cloud Holdings Limited (NASDAQ:KC) Q3 2023 Earnings Call Transcript

Independent Director of ATN International Pamela Lenehan Buys 86% More Shares

Simply Wall St.

2 years ago

Independent Director of ATN International Pamela Lenehan Buys 86% More Shares

Pharming announces first patient dosed in pediatric clinical trial for children aged 1 to 6 years for leniolisib

GlobeNewswire

2 years ago

Pharming announces first patient dosed in pediatric clinical trial for children aged 1 to 6 years for leniolisib

REGENXBIO (NASDAQ:RGNX) adds US$111m to market cap in the past 7 days, though investors from five years ago are still down 72%

Simply Wall St.

2 years ago

REGENXBIO (NASDAQ:RGNX) adds US$111m to market cap in the past 7 days, though investors from five years ago are still down 72%

Inozyme Pharma to Participate in Upcoming Investor Conferences

GlobeNewswire

2 years ago

Inozyme Pharma to Participate in Upcoming Investor Conferences

Inozyme Pharma Reports Third Quarter 2023 Financial Results and Provides Business Highlights

GlobeNewswire

2 years ago

Inozyme Pharma Reports Third Quarter 2023 Financial Results and Provides Business Highlights

Associated Press Finance

2 years ago

Valhi: Q3 Earnings Snapshot

VALHI REPORTS THIRD QUARTER 2023 RESULTS

GlobeNewswire

2 years ago

VALHI REPORTS THIRD QUARTER 2023 RESULTS

Share on Social Networks: